three
year
first
case
describ
middl
east
respiratori
syndrom
mer
coronaviru
continu
caus
sporad
case
commun
well
intermitt
major
hospit
outbreak
poor
infect
control
practic
hospit
overcrowd
delay
diagnos
identifi
root
caus
healthcareassoci
transmiss
case
fatal
rate
approxim
howev
mortal
rate
patient
hospit
lower
respiratori
tract
ill
higher
requir
intens
care
admiss
report
mortal
rate
reach
far
therapi
proven
effect
understand
diseas
pathogenesi
human
remain
incomplet
autopsi
patient
mer
publish
identifi
signific
parenchym
involv
lower
respiratori
tract
review
patient
corman
et
al
identifi
high
protract
viral
replic
lower
respiratori
tract
serious
ill
mer
patient
find
suggest
earli
use
suffici
potent
antivir
regimen
may
benefit
patient
reduc
viral
activ
prevent
lung
damag
decreas
load
viral
shed
among
patient
delay
diagnos
lack
welldefin
anim
model
allow
quick
progress
drug
develop
mer
nevertheless
progress
made
develop
therapeut
discuss
articl
work
still
need
immunotherapi
viralspecif
antibodi
repres
promis
avenu
therapi
mer
consid
high
prioriti
clinic
test
research
protocol
collect
test
convalesc
plasma
previous
infect
patient
infect
patient
goal
transfus
protect
antibodi
mer
patient
formul
protocol
led
establish
network
investig
character
patient
mer
screen
previous
potenti
expos
individu
recent
data
suggest
neutral
antibodi
develop
survivor
individu
could
donat
plasma
clinic
studi
product
hyperimmun
globulin
work
still
progress
determin
whether
feasibl
largescal
therapi
substanti
progress
made
product
merscovspecif
neutral
antibodi
human
well
human
merscov
neutral
antibodi
show
antivir
activ
anim
model
human
polyclon
antibodi
product
gener
cow
use
molecular
technolog
bovin
ig
gene
knock
human
immunoglobulinproduc
gene
insert
genom
addit
mice
genet
modifi
produc
human
monoclon
antibodi
expos
challeng
merscov
antigen
antibodi
produc
larg
quantiti
purifi
neutral
activ
measur
made
avail
test
mer
anim
model
technolog
current
variou
stage
develop
repres
promis
potenti
intervent
may
test
futur
clinic
trial
repurpos
medic
anoth
categori
potenti
therapeut
great
interest
public
health
england
collabor
intern
sever
acut
emerg
respiratori
infect
consortium
isar
identifi
interferon
ribavirin
lopinavir
nitazoxanid
chloroquin
potenti
therapeut
suffici
promis
futur
investig
interferonbeta
ritonavirboost
lopinavir
shown
antivir
effect
common
marmoset
model
mer
howev
none
potenti
therapi
suffici
clinic
data
suggest
use
routin
clinic
care
instead
test
context
appropri
design
clinic
trial
sever
observ
report
evalu
efficaci
interferon
often
use
conjunct
ribavirin
howev
difficult
identifi
true
efficaci
studi
small
sampl
size
need
adequ
address
indic
bia
system
corticosteroid
ribavirin
monotherapi
intraven
immunoglobulin
mycophenol
acidmyophenol
mofetil
appear
associ
greater
likelihood
caus
harm
rather
potenti
benefit
priorit
evalu
evolv
new
evid
continu
reassess
also
ongo
screen
effort
identifi
novel
inhibitor
nucleotid
prodrug
call
inhibit
ebola
macaqu
use
treat
sever
ebola
patient
potent
inhibitor
coronavirus
includ
merscov
vitro
travi
warren
present
icaac
studi
anim
model
progress
episod
natur
merscov
infect
rel
low
number
report
case
given
hospit
region
present
practic
challeng
conduct
clinic
trial
therefor
collabor
among
investig
center
critic
conduct
adequ
power
therapeut
clinic
trial
scientif
valid
clinic
evid
regard
safeti
efficaci
must
drive
inform
incorpor
new
therapeut
clinic
practic
acknowledg
potenti
therapi
ultim
effect
research
infrastructur
consid
adapt
design
allow
comparison
multipl
treatment
regimen
identifi
concurr
control
group
collabor
nation
intern
intellectu
scientif
logist
regulatori
financi
support
alreadi
begun
ksa
nation
intern
investig
develop
draft
protocol
observ
studi
help
identifi
risk
factor
acquir
mer
better
character
clinic
ill
identifi
risk
factor
ill
progress
clarifi
mortal
rate
among
patient
fulfil
case
definit
mer
much
work
alreadi
perform
ksa
intern
hand
protocol
therapeut
trial
promis
potenti
therapi
need
develop
protocol
must
readi
approv
ethic
committe
differ
hospit
must
util
enrol
sporad
patient
well
case
outbreak
also
coordin
center
mandat
support
protocol
develop
prepar
potenti
studi
site
ensur
need
element
place
clinic
trial
irb
approv
consent
form
data
manag
abil
research
coordin
eventu
mechan
share
data
specimen
throughout
nation
intern
scientif
commun
need
establish
research
infrastructur
includ
investig
staff
need
present
mobil
site
quickli
hope
enrol
patient
addit
treatmentbas
evalu
nontreat
base
research
prioriti
gap
address
journey
toward
effect
therapi
mer
could
long
one
certainli
go
exit
articl
present
issu
journal
infect
public
health
reflect
signific
develop
mileston
journey
fund
sourc
none
declar
requir
